Please wait while the formulary information is being retrieved.
ALOPRIM (ALLOPURINOL SODIUM)
- Chemotherapy-induced hyperuricemia
500 mg intravenous solution
- Infuse 200 mg/m2 by intravenous route once daily
500 mg intravenous solution
- Infuse 200 mg/m2 by intravenous route once daily
allopurinol 500 mg intravenous solution
- Infuse 200 mg/m2 by intravenous route once daily
Chemotherapy-induced hyperuricemia
- Infuse 200 mg/m2 by intravenous route once daily
- Infuse 8.333 mg/m2/hour (not to exceed 600 mg/day) by continuous infusion route 24-48 hours before initiation of chemotherapy
- Infuse 16.67 mg/m2/hour (not to exceed 600 mg/day) by continuous infusion route 24-48 hours before initiation of chemotherapy
- Azasan
- azathioprine
- azathioprine sodium
- didanosine
- Imuran
- mercaptopurine
- Purinethol
- Videx 2 Gram Pediatric
- Videx 4 Gram Pediatric
- Videx Ec
Contraindicated
- aminophylline
- Coumadin
- Elixophyllin
- Jantoven
- Theo-24
- Theochron
- theophylline
- theophylline in dextrose 5 %
- warfarin
Severe
Moderate
- None
- HLa-B 58:01 carrier
Contraindicated
- Renal disease with moderate to severe impairment
Severe
Moderate
- Chronic heart failure
- Dehydration
- Disease of liver
ALOPRIM (ALLOPURINOL SODIUM)
- Chemotherapy-induced hyperuricemia
- Allergic dermatitis
- Pruritus of skin
- Skin rash
- Urticaria
- None
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute pancreatitis
- Agranulocytosis
- Anemia
- Aplastic anemia
- Bone marrow depression
- Bradycardia
- Bronchospastic pulmonary disease
- Cataracts
- DRESS syndrome
- Drug-induced hepatitis
- Epistaxis
- Erythema multiforme
- Exfoliative dermatitis
- Gastrointestinal hemorrhage
- Hemolytic anemia
- Hepatic necrosis
- Hypercalcemia
- Hypersensitivity drug reaction
- Jaundice
- Kidney stone
- Lymphadenopathy
- Lymphocytosis
- Nephritis
- Obstructive hyperbilirubinemia
- Onycholysis
- Optic neuritis
- Pancytopenia
- Pericarditis
- Peripheral neuropathy
- Purpura
- Renal failure
- Stevens-johnson syndrome
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
- Vasculitis
Less Severe
- Abdominal pain with cramps
- Acute confusion
- Alopecia
- Amblyopia
- Anorexia
- Arthralgias
- Asthma
- Conjunctivitis
- Depression
- Diarrhea
- Dizziness
- Drowsy
- Dysgeusia
- Dyspepsia
- Ecchymosis
- Edema
- Eosinophilia
- Erectile dysfunction
- Facial edema
- Fever
- Furunculosis
- Gastritis
- General weakness
- Gynecomastia
- Headache disorder
- Hematuria
- Hyperhidrosis
- Insomnia
- Iritis
- Leukocytosis
- Leukopenia
- Libido changes
- Lichen planus
- Male infertility
- Memory impairment
- Myalgias
- Myopathy
- Nausea
- Paresthesia
- Pharyngitis
- Proteinuria
- Rhinitis
- Sialoadenitis
- Stomatitis
- Thrombophlebitis
- Tinnitus
- Vasodilation of blood vessels
- Vertigo
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Allopurinol
- Severity Level:
2
- Additional Notes: Limited data available, congenital malformations in humans have been reported.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Allopurinol
Infant levels may be close to therapeutic levels, monitor for adverse effects
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | No adverse effect | Infant levels may be close to therapeutic levels, monitor for adverse effects |
Contraindicated
None
Precaution Exists
Allopurinol
Renal-Due to renal elimination, dose reduction or increase dosing interval may be required to avoid toxicities resulting from accumulation of allopurinol or its metabolites.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Chemotherapy-induced hyperuricemia | |
| E88.3 | Tumor lysis syndrome |
| 0-9 | A-Z |
|---|---|
| E88.3 | Tumor lysis syndrome |
Formulary Reference Tool